Your browser doesn't support javascript.
loading
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja, Kristyn; Lanke, Shankar; Munafo, Alain; Victor, Anja; Habermehl, Christina; Schueler, Armin; Venkatakrishnan, Karthik; Girard, Pascal; Goteti, Kosalaram.
Afiliación
  • Pantoja K; Department of Statistics, Texas A&M University, College Station, Texas, USA.
  • Lanke S; EMD Serono Research Institute, Billerica, Massachusetts, USA.
  • Munafo A; EMD Serono Research Institute, Billerica, Massachusetts, USA.
  • Victor A; Merck Institute for Pharmacometrics, Lausanne, Switzerland.
  • Habermehl C; Merck KGaA, Darmstadt, Germany.
  • Schueler A; Merck KGaA, Darmstadt, Germany.
  • Venkatakrishnan K; Merck KGaA, Darmstadt, Germany.
  • Girard P; EMD Serono Research Institute, Billerica, Massachusetts, USA.
  • Goteti K; Merck Institute for Pharmacometrics, Lausanne, Switzerland.
CPT Pharmacometrics Syst Pharmacol ; 11(10): 1371-1381, 2022 10.
Article en En | MEDLINE | ID: mdl-35852048
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos